At Illumina, the ‘era of the genome’ has arrived. But what role will the company play?

“We are exiting the pandemic, and entering the era of the genome,” deSouza said. He thinks that the pandemic has, in fact, accelerated the science and its adoption by perhaps five years. And he also believes that public discussions around genetics — previously focused on threats — may have shifted, thanks in part to the vaccines, to possibilities.